Source:http://linkedlifedata.com/resource/pubmed/id/10087180
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-4-29
|
pubmed:abstractText |
The systemic adoptive transfer of activated T cells, derived from tumor-draining lymph nodes (LNs), mediates the regression of established tumors. In this study, the requirement of cell adhesion molecules, CD11a/CD18 (LFA-1), CD54 (ICAM-1), CD49d/CD29 (VLA-4), and CD106 (VCAM-1), for T cell infiltration into tumors and antitumor function was investigated. Administration of anti-CD11a mAb completely abrogated the efficacy of adoptive immunotherapy for both intracranial and pulmonary metastatic MCA 205 fibrosarcomas. In contrast, adoptive immunotherapy was effective in animals treated with anti-CD49d mAb, anti-CD106 mAb, anti-CD54 mAb, or in CD54 knockout recipients. Trafficking of transferred cells to the intracranial tumor was not affected by any of the mAb. However, the tumor-specific secretion of IFN-gamma by activated LN T cells was suppressed by anti-CD11a mAb or anti-CD54 mAb. To account for the different effects of CD11a and CD54 blockade in vivo, an additional CD11a/CD18 ligand, CD102 (ICAM-2), was demonstrated on tumor-associated macrophages but not on tumor cells. These results show that CD11a mediates a critical function in interactions between effector T cells, tumor cells, and host accessory cells in situ leading to tumor regression.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphocyte Function-Associated...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0008-8749
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 1999 Academic Press.
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
192
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
122-32
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:10087180-Animals,
pubmed-meshheading:10087180-Antibodies, Monoclonal,
pubmed-meshheading:10087180-Brain Neoplasms,
pubmed-meshheading:10087180-Cell Movement,
pubmed-meshheading:10087180-Female,
pubmed-meshheading:10087180-Immunotherapy, Adoptive,
pubmed-meshheading:10087180-Intercellular Adhesion Molecule-1,
pubmed-meshheading:10087180-Interferon-gamma,
pubmed-meshheading:10087180-Lung Neoplasms,
pubmed-meshheading:10087180-Lymphocyte Function-Associated Antigen-1,
pubmed-meshheading:10087180-Macrophages,
pubmed-meshheading:10087180-Mice,
pubmed-meshheading:10087180-Mice, Inbred C57BL,
pubmed-meshheading:10087180-Mice, Inbred DBA,
pubmed-meshheading:10087180-Neoplasms, Experimental,
pubmed-meshheading:10087180-T-Lymphocytes
|
pubmed:year |
1999
|
pubmed:articleTitle |
Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.
|
pubmed:affiliation |
Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|